TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06798090

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Band and Loop Space Maintainer Produced with Conventional Technique
Description: Band and loop space maintainer produced with conventional methods
Study: NCT06798103

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae Plane Block
Description: Erector spinae plane block will be performed using an ultrasound machine with a high frequency linear probe. The patients will be in sitting position to perform the block, the skin is sterilized and the transducer will be placed across the T7 spinous process then move laterally to identify transverse process of T7. Thereafter, the probe will be moved to a parasagittal plane to visualize skin and subcutaneous tissue layers, trapezius muscle, and lastly the erector spinae muscle just superficial to the transverse processes. The in-plane technique will be used, and the tip of the needle will be inserted in the fascial plane deep to the erector spinae muscle. After 2-3 mL of normal saline injection for hydro dissection to verify the correct needle tip placement, 30 mL of 0.25% bupivacaine will be injected deep to the erector spinae muscle. The same technique will be repeated on the contralateral side.
Study: NCT05476887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KP104
Description: KP104 intravenously (IV loading + subcutaneous \[SC\] maintenance every week \[QW\] or every 2 weeks \[Q2W\]) will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KP104
Description: KP104 intravenously (IV loading + subcutaneous \[SC\] maintenance every week \[QW\] or every 2 weeks \[Q2W\]) will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KP104
Description: KP104 intravenously (IV loading + subcutaneous \[SC\] maintenance every week \[QW\] or every 2 weeks \[Q2W\]) will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KP104
Description: KP104 intravenously (IV loading + subcutaneous \[SC\] maintenance every week \[QW\] or every 2 weeks \[Q2W\]) will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KP104
Description: KP104 intravenously (IV loading + subcutaneous \[SC\] maintenance every week \[QW\] or every 2 weeks \[Q2W\]) will be administered.
Study: NCT05033587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib a multi-target receptor tyrosine kinase inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK105
Description: AK105 is a humanized monoclonal antibody that specifically binds to PD-1.
Study: NCT06798103

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic paravertebral block
Description: Thoracic paravertebral block will be performed using an ultrasound machine with a high frequency linear probe. The patients will be in sitting position to perform the block, the skin is sterilized and the transducer will be placed across the T7 spinous process then move laterally to identify transverse process of T7. Thereafter, the probe will be moved 3-5 cm laterally to identify the paravertebral space as the target injection site. After probe being rotated into transverse orientation, the needle will be inserted using the out-plane technique. Once the needle threads the internal intercostal membrane and arrives in the paravertebral space, 3 ml of normal saline will be injected firstly. If displacement sign of the pleura occurs, 25 ml of 0.25% bupivacaine will be then injected into the confirmed paravertebral space. The same technique will be repeated on the contralateral side.
Study: NCT06797843

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SPRG-based Resin Composite : (BEAUTIFIL II, Shofu Inc. Kyoto, Japan).
Description: A fluoride releasing, highly aesthetic dental material that is S-PRG (Surface Pre-reacted Glass Ionomer) based , has the ability to recharge fluoride and appropriate for patients with a high caries index.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alkasite based restoration : Cention N
Description: Cention N offers tooth-coloured esthetics together with high flexural strength. The new filling material belongs to the materials group of Alkasites. The patented alkaline filler increases the release of hydroxide ions to regulate the pH value during acid attacks. As a result, demineralization can be prevented. Moreover, the release of large numbers of fluoride and calcium ions forms a sound basis for the remineralization of dental enamel. The initiator system enables good chemical self-curing.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: provisional Resin modified glass ionomer followed by Nanohybrid composite
Description: GC Fuji IX GP® EXTRA is the fastest setting glass ionomer on the market.The faster final set saves valuable chair time which provides improved stability against water, an important feature in challenging oral environments. This product contains a next generation glass filler which elicits higher translucency, fluoride release, reactivity and a faster setting time.~Then followed by Conventional Nano hybrid composite restoration(Neo Spectra® ST LV, Dentsply Sirona) which is nano-ceramic, light-cured, radiopaque, universal composite with novel SphereTEC filler technology.
Study: NCT06800170

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: myo-Inositol plus DIoscorea Villosa
Description: myo-Inositol + alpha-lactalbumin + folic acid once daily, Dioscorea Villosa + alpha-lactalbumin + Vitamin D twice daily
Study: NCT06798649

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The intervention in the GESTACOR study involves providing detailed feedback from vascular imaging to women who have experienced adverse pregnancy outcomes (APOs).
Description: This is aimed at assessing whether such feedback can encourage the adoption of healthier lifestyles and enhance adherence to preventive treatments, thereby potentially reducing the incidence of postpartum hypertension and other cardiovascular diseases.~Components of the Intervention:~Vascular Imaging:~Women in the intervention group undergo advanced vascular imaging using ultrasound technology to detect the presence of arterial plaques vs. no information about vascular images in the standard manag group.~The images are analyzed to assess the extent of vascular health, focusing on areas typically affected by cardiovascular risks such as the carotid arteries.~Feedback Delivery:~Detailed results from the vascular imaging are provided to the participants in a comprehensible format by healthcare professionals specialized in cardiovascular health.~This feedback session includes a thorough explanation of the findings, highlighting areas of concern and potential risks.
Study: NCT06799806

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: virtual reality device
Description: 20 minutes session with virtual reality device
Study: NCT06799949

Intervention type: DIAGNOSTIC_TEST
Intervention: ROTEM (TEM Innovations GmbH, Munich, Germany) assay
Description: For each patient, two samples will be collected for ROTEM analysis: one at the beginning of the surgery during the placement of the arterial line (Start ratio) and another at the end during the completion of the surgical wound closure(Final ratio). The arterial line system will be filled with normal saline (0.9% sodium chloride) without the addition of unfractionated heparin. To avoid sample contamination before sampling, a volume of blood equivalent to 5.5-6 times the dead space (calculated from the catheter tip to the three-way stopcock device) will be aspirated. Blood samples for testing will be stored in specialized evacuated coagulation test tubes (Jiangsu Rongye Technology Co., Ltd, Jiangsu, China) and gently mixed with 3.2%-0.109M sodium citrate, for a total volume of 1.8 ml.
Study: NCT05238454

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCTV01C
Description: intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Sinopharm inactivated COVID-19 vaccine
Description: intramuscular injection
Study: NCT06799195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Attenuated-dose Cyclophosphamide
Description: Cyclophosphamide administered at an attenuated dose of 25 mg/kg on days +3 and +4 post-transplant for GVHD prophylaxis.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High-dose Cyclophosphamide
Description: Cyclophosphamide administered at the standard high dose of 50 mg/kg on days +3 and +4 post-transplant for GVHD prophylaxis.
Study: NCT05238454

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comirnaty
Description: intramuscular injection
Study: NCT05033587

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: The radiotherapy regimen delivered 2.0Gy once a day, five days a week to a total dose of 60Gy.
Study: NCT06292936

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance-Based Behavioral Intervention
Description: Intervention will evaluate acceptance-based behavioral treatment (ABT) for individuals who are experiencing weight regain after bariatric surgery. ABT builds acceptance and mindfulness skills that increase the capacity to experience uncomfortable internal states (e.g., food cravings, hunger, negative affect). Online treatments include video modules demonstrating session content as well as interactive features. These interventions are particularly desirable, reduced participant burden, and are cost effective.~ABT provides patients unique skills that directly target causes of dietary non-adherence. ABT provides patients specialized skills to directly target causes of dietary nonadherence (rather that solely repeating behavioral strategies they received during preoperative medical weight management required by their third party payers and bariatric surgery programs).
Study: NCT06799195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus is started on day +5 with a loading dose of 6 mg, followed by a maintenance dose of 2 mg daily, adjusted to target trough levels of 8-12 ng/mL. Sirolimus taper is recommended to start at day +90 and to be completed by day +180, provided there is no evidence of acute GVHD.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus
Description: Sirolimus is started on day +5 with a loading dose of 6 mg, followed by a maintenance dose of 2 mg daily, adjusted to target trough levels of 8-12 ng/mL. Sirolimus taper is recommended to start at day +90 and to be completed by day +180, provided there is no evidence of acute GVHD.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil (MMF)
Description: MMF is started on day +5 at a dose of 15 mg/kg per dose (maximum 1 g per dose) three times daily. MMF is generally discontinued by day +35 in the absence of GVHD.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil (MMF)
Description: MMF is started on day +5 at a dose of 15 mg/kg per dose (maximum 1 g per dose) three times daily. MMF is generally discontinued by day +35 in the absence of GVHD.
Study: NCT06798675

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nC-001
Description: solid dosage form single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nC-001
Description: solid dosage form single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06798337

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Physiotherapy group
Description: Participants in the regular physical therapy group performed balance and coordination exercises three times a week without the use of rewards. These subjects completed only physical exercises, without engaging in game-like interactive tasks using virtual reality (VR) glasses. Each session was conducted at the same time for each subject, with a potential variation of ±1 hour.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reward based physiotherapy group
Description: Subjects in the reward group performed balance and coordination exercises three times a week, with the inclusion of rewards. At the end of each exercise session, participants engaged in game-like interactive tasks using virtual reality (VR) glasses. Exercise sessions were conducted at the same time for each subject, with a permissible variation of ±1 hour.
Study: NCT06797856

Intervention type: DIAGNOSTIC_TEST
Intervention: Refractive Error
Description: * Refractive error centrally (on-axis) and peripherally in both nasal and temporal visual fields~* Ocular wavefront measured centrally (on-axis) and peripherally in both nasal and temporal visual fields
Study: NCT05665244

Intervention type: PROCEDURE
Intervention: Laryngeal cryotherapy
Description: Laryngeal cryotherapy is the therapeutic freezing of tissue in the throat to numb the overactive sensory nerves in the throat. This technique is believed to reduce cough symptoms in this study.

Intervention type: DEVICE
Intervention: Cryoprobe
Description: Cryoprobe is FDA approved for use for the destruction of unwanted tissue along the respiratory tract
Study: NCT04783220

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive structured parent intervention
Description: 1. Educational sessions and coaching on infants' behavior cues~2. Skills on motor stimulation~3. Written instructions for play and stimulation activities at discharge~4. Multidisciplinary follow-up~5. Developmental tracking and advice via a mobile app
Study: NCT06639217

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: a comprehensive nursing care protocol
Description: a comprehensive nursing care protocol provided for nurses who provide direct care for women with pelvic organ prolapse and urinary incontinence on their knowledge and practices as well as its impact on the women quality of life
Study: NCT05778071

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: eneboparatide
Description: Supplied as a solution (concentration of 250 mcg/mL or 500 mcg/mL) in single-patient-use prefilled pens

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is supplied as a solution (containing the excipient solution for eneboparatide) in single-patient-use prefilled pens
Study: NCT06112288

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Compressive Myofascial Release
Description: Compressive myofascial release is manual therapy technics.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ankle mobilisation
Description: ankle mobilization is manual therapy technics.
Study: NCT05807256

Intervention type: OTHER
Intervention: collection and analysis of treatments and procedures already performed by normal clinical practice
Description: The patients' anthropometric variables; laboratory test results; PMA techniques (types of fertilization/drugs used for stimulation) and the outcome of the eventual pregnancy (ongoing treatment during the pregnancy itself, development of maternal/fetal complications, such as hypertension, preeclmpsia, thrombotic events, renal failure, disease flare, neonatal outcome) and data on the type of ovarian stimulation drug treatment.
Study: NCT05016817

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AlloRx
Description: cultured allogeneic adult umbilical cord derived mesenchymal stem cells
Study: NCT05970003

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Copenhagen exercises
Description: Group A performs copenhagen exercises~Both groups will perform their routine warm ups and cool downs the total duration of the protocol is 6 weeks, 3 times a week the duration of each session 3 sets of 10 repetitions with 15 sec recovery period. Hip extensor and flexor stretching and strengthening.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Holmich exercises
Description: The Holmich treatment protocol exercise includes static and dynamic and/or isometric and isotonic strengthening exercises for hip adductors and abductors and also for abdominal muscles.~There are 6 Different types of exercises were performed by players who were a participant with 3 sets of 10 repetitions with 15 sec recovery period.~Both groups will perform their routine warm ups and cool downs the total duration of the protocol is 6 weeks, 3 times a week the duration of each session 3 sets of 10 repetitions with 15 sec recovery period. Hip extensor and flexor stretching and strengthening.
Study: NCT05968170

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS® device
Description: CliniMACS TCR αβ+/CD19+ cell depletion for related or unrelated haploidentical/mismatched/matched hematopoietic stem cell transplant patients and/or high risk GVHD patients.
Study: NCT05877872

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reduced-target resection
Description: Patients receive surgery according to pSTV-post-IC.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Full-target resection
Description: Patients receive surgery according to pSTV-pre-IC.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvant immunotherapy
Description: Toripalimab(240 mg d1) continually applied since 1-2 weeks after surgery until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, investigator decision, or 1 year.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant immunotherapy
Description: Toripalimab(240 mg d1) continually applied since 1-2 weeks after surgery until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, investigator decision, or 1 year.
Study: NCT05964426

Intervention type: OTHER
Intervention: Turkey Health Literacy Scale (TSOY-32)
Description: A survey will be conducted.

Intervention type: OTHER
Intervention: Turkey Health Literacy Scale (TSOY-32)
Description: A survey will be conducted.

Intervention type: OTHER
Intervention: Turkey Health Literacy Scale (TSOY-32)
Description: A survey will be conducted.
Study: NCT05909449

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercises
Description: participants will be given a structured home exercise program
Study: NCT06062641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SR-GDP
Description: Selinexor 40mg/d，po d1,8,15; rituximab 375mg/m2, iv d1; gemcitabine 1g/m2, iv d1,8; cisplatin 25mg/m2, iv d1-3; dexamethasone 40mg，po/iv d1-4 (If patient\>70y, the dosage should be changed to 20mg). Each cycle lasts for 21 days, with a maximum of 6 cycles of combination therapy. For patients who achieved PR or better response at the end of combination therapy, they will start receiving single-agent selinexor 40mg treatment (qw) in cycles of 28 days until disease progression (PD) or unacceptable toxicity occurs.
Study: NCT05758506

Intervention type: DEVICE
Intervention: Primary Immunodeficiency (PID) Rapid Diagnostic Test (RDT)
Description: We are evaluating the accuracy of a new rapid diagnostic screening test. There is no medical intervention with the participants in this study.

Intervention type: DEVICE
Intervention: Primary Immunodeficiency (PID) Rapid Diagnostic Test (RDT)
Description: We are evaluating the accuracy of a new rapid diagnostic screening test. There is no medical intervention with the participants in this study.

Intervention type: DEVICE
Intervention: Primary Immunodeficiency (PID) Rapid Diagnostic Test (RDT)
Description: We are evaluating the accuracy of a new rapid diagnostic screening test. There is no medical intervention with the participants in this study.
Study: NCT05892562

Intervention type: OTHER
Intervention: No intervention
Description: As this study is purely observational, no intervention is involved.

Intervention type: OTHER
Intervention: No intervention
Description: As this study is purely observational, no intervention is involved.
Study: NCT04955951

Intervention type: DEVICE
Intervention: polarized light
Description: A Bioptron light therapy phototherapeutic device (Bioptron AG, Wollerau, Switzerland) with 5 cm treatment diameter (BIOPTRON MedAll®, 480-3400 nm, polarization level of 95%, power density 40 mW/cm2, energy density 2,4 J/cm2 per minute

Intervention type: DRUG
Intervention: Topical corticosteroid ointment
Description: corticosteroid 1 %.
Study: NCT05564468

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive standard of care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention
Description: Receive Peacefully's end-of-life planning program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05179265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human serum albumin
Description: 10 g/bottle (20%, 50 mL)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Human serum albumin
Description: 10 g/bottle (20%, 50 mL)
Study: NCT06509022

Intervention type: DIAGNOSTIC_TEST
Intervention: PEPTEST test
Description: Quantitative determination of gastric salivary amylase。

Intervention type: DIAGNOSTIC_TEST
Intervention: PEPTEST test
Description: Quantitative determination of gastric salivary amylase。

Intervention type: DIAGNOSTIC_TEST
Intervention: PEPTEST test
Description: Quantitative determination of gastric salivary amylase。

Intervention type: DIAGNOSTIC_TEST
Intervention: PEPTEST test
Description: Quantitative determination of gastric salivary amylase。

Intervention type: DIAGNOSTIC_TEST
Intervention: PEPTEST test
Description: Quantitative determination of gastric salivary amylase。
Study: NCT06487481

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Preoperative external beam radiation therapy (EBRT)
Description: Preoperative external beam radiation therapy (EBRT) at escalating doses daily 5 days/week (M-F) for 2-3 weeks; 2 weeks (DL1), or 3 weeks (DL2 or DL3) based on assigned Cohort and Dose Level (DL). Cohorts are by mitotane status at enrollment: Cohort 1 (with detectable mitotane levels), Cohort 2 (never had or without detectable mitotane levels), Cohort 3 (either).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical resection
Description: Planned surgical resection (all participants) 4-8 weeks after completion of the preoperative radiotherapy (EBRT)
Study: NCT06169943

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mHealth social support program
Description: This is a 3-month program comprises mobile app, group discussion, individual telephone contact, and reminders.

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: The same mobile app as the intervention group but with limited function.